October 4, 2024 — Caution is wise when observational studies compete for our attention. But this one, from JAMA Network Open, is intriguing. In a recent analysis of 33,006 persons with both type 2 diabetes and opioid use disorder, researchers found a signal that semaglutide might lower the risk of opioid overdoses by as much as two-thirds. “It’s a […]
July 31, 2024 — A fascinating new study in Annals of Internal Medicine asks an important question. When people receive semaglutide for type 2 diabetes, are they less likely to smoke? This is not such a random question. In fact, clinicians are reporting striking reductions in addictive behaviors by people receiving it for obesity. So William Wang and colleagues […]
July 11, 2023 — The emergence of advanced medicines for obesity is teaching us a lot about the overlapping mechanisms that drive desires for alcohol, food, and more. Desire, it seems, is more than just a feeling. It is the product of biological processes that our bodies regulate. But those processes can clearly go astray, and desire for food, […]
